Patients on strong opioids may have genetic anomalies, study says | Migraine without aura may have cognitive implications | AHS updates cluster headache guidelines
September 14, 2016
News for the pain professional
Pain Research News
Patients on strong opioids may have genetic anomalies, study says
Research presented at the PAINWeek conference showed 91% of chronic pain patients taking high-dose opioids had genetic anomalies that may affect their drug metabolism. Researcher Forest Tennant said practitioners prescribing high levels of opioids should consider genetic testing for their patients.
MedPage Today (free registration) (9/11) 
LinkedIn Twitter Facebook Google+ Email
Migraine without aura may have cognitive implications
A study in the Journal of Headache and Pain found patients who had migraines without aura had lower scores on cognitive tests, compared with a control group. Researchers said the scores were not below cut-off levels so cognitive decline was not clinically relevant, but added identifying deficits early could be important to future care planning.
MedPage Today (free registration) (9/8) 
LinkedIn Twitter Facebook Google+ Email
Let's heal healthcare.
Healthcare is complex. And change is easier said than done. This is why leaders from across the industry select the Executive Master of Healthcare Leadership from Brown University. Learn with the best, solve problems, and develop a lasting network. Make change happen.
Click here to learn more.
Treatment News
AHS updates cluster headache guidelines
Updated guidelines released by the American Headache Society show sumatriptan, subcutaneous zolmitriptan nasal spray and high flow oxygen continue to be Level A-recommended treatments for acute cluster headaches. The guidelines, published in the journal Headache, include a review of non-medication therapies but do not consider pediatric cluster headaches or treatments for the elderly and pregnant or lactating women.
MedPage Today (free registration) (9/11) 
LinkedIn Twitter Facebook Google+ Email
Study finds OIC drug safe to take for 1 year
Naldemedine may be safely taken to treat opioid-induced constipation for up to one year, researchers reported at PAINWeek 2016. The study included about 620 adults with opioid-induced constipation and chronic noncancer pain who received the drug, and a similar number of patients who took a placebo.
Healio (free registration)/Gastroenterology (9/12) 
LinkedIn Twitter Facebook Google+ Email
Other News
Policy & Trends
Expert: US has two pain-related epidemics
Public health in the US is dealing with an opioid drug abuse epidemic and a less-publicized chronic pain epidemic, Steven Passik, senior director at Endo Pharmaceuticals, said during the PAINWeek 2016 conference keynote lecture. He said society's perception of opioid prescribing has made it difficult for pain management professionals to do their job, but rather than hesitating to treat pain, the field should take the approach of using research that shows successful outcomes when alterations are made in opioid use. (9/11) 
LinkedIn Twitter Facebook Google+ Email
Researcher outlines ways to prevent substance abuse in pain patients
A researcher told the PAINWeek 2016 conference the best ways to minimize the risk of substance abuse among chronic pain patients include routine assessments and signed agreements between providers and patients. David Cosio of Chicago's Jesse Brown VA Medical Center said practitioners also need to watch for symptoms that a patient may be developing a substance abuse disorder.
MedPage Today (free registration) (9/8) 
LinkedIn Twitter Facebook Google+ Email
Other News
APS News
NEW Edition! Principles of Analgesic Use, Seventh Edition
Both current evidence and expert consensus opinion support the use of analgesic drugs as an important part of multimodal primary care or specialty management of pain. This guide identifies where the evidence does and does not support a treatment modality as well as providing a recommendation.

The American Pain Society provides this expert review of best pain practices to assist the practitioner in better managing their patients' pain with analgesic drugs. Buy it online now.

LinkedIn Twitter Facebook Google+ Email
Submit your poster abstract and present at the 2017 Annual Scientific Meeting!
The APS Scientific Program Committee (SPC) invites you to submit a poster abstract and present to hundreds of pain professionals at the 2017 Annual Scientific Meeting in Pittsburgh.

The SPC is seeking original research that has not been previously presented or published elsewhere, prior to the APS meeting. All accepted posters will be presented at the 2017 Annual Scientific Meeting, May 17-20, 2017, and will be published in a supplement to The Journal of Pain. Learn more.

LinkedIn Twitter Facebook Google+ Email
Excellent firms don't believe in excellence -- only in constant improvement and constant change.
Tom Peters,
writer and management consultant
LinkedIn Twitter Facebook Google+ Email
Learn more about APS:
Membership | Annual Meeting | Education
Funding Opportunities | About Us
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Partner Relations Manager  -  Lauren Barr
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information